Shopping Cart

Clostridium difficile Infections-Pipeline Review, H1 2017

SKU
GMDHC9252IDB
READ MORE
USD 2,000
Single User License
USD 2,000
Site License
USD 4,000
Corporate User License
USD 6,000

Clostridium difficile Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections-Pipeline Review, H1 2017, provides an overview o

READ MORE
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Clostridium difficile Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections-Pipeline Review, H1 2017, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 11, 29, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Overview 9

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 20

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Companies Involved in Therapeutics Development 29

Absynth Biologics Ltd 29

Actelion Ltd 29

AIMM Therapeutics BV 30

Akthelia Pharmaceuticals Ltd 30

AmpliPhi Biosciences Corp 31

Appili Therapeutics 31

Assembly Biosciences Inc 32

AvidBiotics Corp 32

C3J Therapeutics Inc 33

CaroGen Corp 33

Crestone Inc 34

Da Volterra SAS 34

Daiichi Sankyo Company Ltd 35

Evec Inc 35

GangaGen Inc 36

ImmunoBiology Ltd 36

Immuron Ltd 37

Inovio Pharmaceuticals Inc 37

Integrated BioTherapeutics Inc 38

Merck & Co Inc 38

MGB Biopharma Ltd 39

Microbiotix Inc 39

Micropharm Ltd 40

Miyarisan Pharmaceutical Company Ltd 40

Nabriva Therapeutics AG 41

Nanotherapeutics Inc 41

Novabiotics Ltd 42

NovoBiotic Pharmaceuticals LLC 42

Oragenics Inc 43

Otsuka Holdings Co Ltd 43

Pfizer Inc 44

Prokarium Ltd 44

Rebiotix Inc 45

Sanofi Pasteur SA 45

Second Genome Inc 46

Seres Therapeutics Inc 46

Serometrix LLC 47

Sorrento Therapeutics Inc 47

Summit Therapeutics Plc 48

Synthetic Biologics Inc 48

Valevia UK Ltd 49

Valneva SE 49

XBiotech Inc 50

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Drug Profiles 51

ABCD-01-Drug Profile 51

ABIM-101-Drug Profile 53

AKT-10081-Drug Profile 54

Antibodies for Enterocolitis-Drug Profile 55

Antibodies to Inhibit Toxin A and Toxin B for Clostridium difficile Infections-Drug Profile 56

AvR2-V10-Drug Profile 57

Biologic for Clostridium difficile Infections-Drug Profile 59

Biologics for Clostridium Difficile Infections-Drug Profile 60

cadazolid-Drug Profile 61

CBM-588-Drug Profile 63

CD-17DL-Drug Profile 65

Cdiff Snare-Drug Profile 66

clofazimine-Drug Profile 67

Clostridium difficile (virus like particle) vaccine-Drug Profile 68

Clostridium difficile vaccine-Drug Profile 69

Clostridium difficile vaccine-Drug Profile 71

Clostridium difficile vaccine-Drug Profile 72

Clostridium difficile vaccine-Drug Profile 73

clostridium difficile vaccine-Drug Profile 75

Clostridium difficile vaccine-Drug Profile 76

Clostridium difficile vaccine-Drug Profile 77

Clostridium difficile vaccine-Drug Profile 78

Clostridium difficile vaccine-Drug Profile 79

Clostridium difficile vaccine-Drug Profile 80

CP-101-Drug Profile 81

CRS-3123-Drug Profile 82

DAV-132-Drug Profile 83

DiffiKil-Drug Profile 84

Drugs for Clostridium difficile Infections-Drug Profile 85

DS-2969-Drug Profile 86

EV-029104-Drug Profile 87

EV-029105A-Drug Profile 88

fidaxomicin-Drug Profile 89

FIN-403-Drug Profile 96

IMM-529-Drug Profile 97

INS-5010-Drug Profile 98

MBX-500-Drug Profile 99

MCB-3681-Drug Profile 101

MCB-3837-Drug Profile 102

metronidazole-Drug Profile 103

MGBBP-3-Drug Profile 104

Monoclonal Antibodies for Clostridium difficile Infections-Drug Profile 107

Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections-Drug Profile 108

Monoclonal Antibody for Clostridium Difficile Infections-Drug Profile 109

Monoclonal Antibody for Clostridium Difficile Infections-Drug Profile 110

Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections-Drug Profile 111

NP-432-Drug Profile 112

OG-253-Drug Profile 113

OG-716-Drug Profile 115

OPS-2071-Drug Profile 116

OraCAb-Drug Profile 117

P-100031-Drug Profile 118

P-4A-Drug Profile 119

PF-06425090-Drug Profile 120

PolyCAb-Drug Profile 122

Polymers for Clostridium difficile Infections and Candidiasis-Drug Profile 123

ramoplanin-Drug Profile 124

RBX-2660-Drug Profile 125

RBX-7455-Drug Profile 128

ribaxamase-Drug Profile 129

ridinilazole-Drug Profile 135

SER-109-Drug Profile 141

SER-262-Drug Profile 145

SHP-01-Drug Profile 146

Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections-Drug Profile 147

Small Molecules for Clostridium Difficile Infections-Drug Profile 148

Small Molecules for Clostridium Difficile Infections-Drug Profile 149

Small Molecules for Clostridium difficile Infections-Drug Profile 150

Small Molecules to Inhibit 23S rRNA for Clostridium difficile and Helicobacter pylori Infections-Drug Profile 151

Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections-Drug Profile 152

Small Molecules to Inhibit DNA Synthesis for Infectious Diseases-Drug Profile 153

Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections-Drug Profile 154

Small Molecules to Inhibit Metalloprotease for Clostridium difficile Infections-Drug Profile 155

Small Molecules to Inhibit Toxin A and Toxin B for Clostridium Difficile Infections-Drug Profile 156

SQ-641-Drug Profile 157

SYN-006-Drug Profile 159

SYN-007-Drug Profile 160

TNP-2092-Drug Profile 161

VAL-301-Drug Profile 162

VE-303-Drug Profile 163

VLA-84-Drug Profile 164

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Dormant Projects 167

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Discontinued Products 170

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Product Development Milestones 171

Featured News & Press Releases 171

Appendix 182

Methodology 182

Coverage 182

Secondary Research 182

Primary Research 182

Expert Panel Validation 182

Contact Us 182

Disclaimer 183


List Of Figure

List of Figures

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Absynth Biologics Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Actelion Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by AIMM Therapeutics BV, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by AmpliPhi Biosciences Corp, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Appili Therapeutics, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Assembly Biosciences Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by AvidBiotics Corp, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by C3J Therapeutics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by CaroGen Corp, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Crestone Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Da Volterra SAS, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Evec Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by GangaGen Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by ImmunoBiology Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Immuron Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Integrated BioTherapeutics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Merck & Co Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by MGB Biopharma Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Microbiotix Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Micropharm Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Nabriva Therapeutics AG, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Nanotherapeutics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Novabiotics Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Oragenics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Otsuka Holdings Co Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Pfizer Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Prokarium Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Rebiotix Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Sanofi Pasteur SA, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Second Genome Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Seres Therapeutics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Serometrix LLC, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Sorrento Therapeutics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Summit Therapeutics Plc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Synthetic Biologics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Valevia UK Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by Valneva SE, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline by XBiotech Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Dormant Projects, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease)-Discontinued Products, H1 2017

To know more information on Purchase by Section, please send a mail to

Products

Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutic Products under Development, Key Players in Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Clostridium difficile Infections (Clostridium difficile Associated Disease) Pipeline Overview, Clostridium difficile Infections (Clostridium difficile Associated Disease) Pipeline, Clostridium difficile Infections (Clostridium difficile Associated Disease) Pipeline Assessment

Companies

Absynth Biologics Ltd, Actelion Ltd, AIMM Therapeutics BV, Akthelia Pharmaceuticals Ltd, AmpliPhi Biosciences Corp, Appili Therapeutics, Assembly Biosciences Inc, AvidBiotics Corp, C3J Therapeutics Inc, CaroGen Corp, Crestone Inc, Da Volterra SAS, Daiichi Sankyo Company Ltd, Evec Inc, GangaGen Inc, ImmunoBiology Ltd, Immuron Ltd, Inovio Pharmaceuticals Inc, Integrated BioTherapeutics Inc, Merck & Co Inc, MGB Biopharma Ltd, Microbiotix Inc, Micropharm Ltd, Miyarisan Pharmaceutical Company Ltd, Nabriva Therapeutics AG, Nanotherapeutics Inc, Novabiotics Ltd, NovoBiotic Pharmaceuticals LLC, Oragenics Inc, Otsuka Holdings Co Ltd, Pfizer Inc, Prokarium Ltd, Rebiotix Inc, Sanofi Pasteur SA, Second Genome Inc, Seres Therapeutics Inc, Serometrix LLC, Sorrento Therapeutics Inc, Summit Therapeutics Plc, Synthetic Biologics Inc, Valevia UK Ltd, Valneva SE, XBiotech Inc

Brand Description
History Color sit amet, consectetur adipiscing elit. In gravida pellentesque ligula, vel eleifend turpis blandit vel. Nam quis lorem ut mi mattis ullamcorper ac quis dui. Vestibulum et scelerisque ante, eu sodales mi. Nunc tincidunt tempus varius. Integer ante dolor, suscipit non faucibus a, scelerisque vitae sapien.